| This was sent to me from the Hotcopper Team and was in my junk...

	Column 1	Column 2
0		This was sent to me from the Hotcopper Team and was in my junk mail with the tittle "One of the best value Biotech plays on the ASX". Check your junk mail folder it will have a whole bunch of mail from the HC Team It included a link to their website and the latest video from their website with Dr Investment talking about their trials in the states I wonder how much Virax payed them for the PR?
1		VIRAX Two new cancer drugs and five clinical trials running in next 12 months = strong newsflow with key milestone success to drive share price One to watch right now in the biotech sector is Virax Holdings Limited (VHL). This company last week announced moves to acquire a US company called AKTivate Therapeutics and its novel cancer drug called TCN-P. We like this because TCN-P is already being trialled on patients at some of the biggest cancer centres in the US as a potential new treatment for breast and ovarian cancer, with a leukaemia trial to start early next year. All signs so far suggest this drug could be a new way of treating cancer around the world. Some of the biggest names in US cancer medicine are involved in the trials at the Moffitt Cancer Center and the Montefiore Cancer Center in New York. This takeover is subject to shareholder approval in November but is expected to proceed without a hitch. What's more, it comes on the back of VHL's other acquisition earlier this year of US Pathway Oncology and its cancer drug GGTI-2418. This drug is also in mid stage development with trials soon to get underway in breast cancer and multiple myeloma. This means VHL has two drugs in five clinical trials over the next 12 months, under two separate INDs (basically a green light from the Food and Drug Administration). Two of these trials are fully funded by US Government authorities (Dept of Defense and National Cancer Institute). The drugs are made, so there is no manufacturing risk. The two drugs are different but VHL says they can work together and basically kill cancer cells by attacking them from different avenues. The aim is these drugs will be used alongside current chemo drugs marketed by big pharma to improve survival times and quality of life. MD Dr Rob Crombie comes with a strong commercialisation background — he took Arana Therapeutics from a start up to a $320 million trade sale in less than five years -- and he says the company plans to continue trials of both drugs at the same time. So, strong news flow expected over the next 12 months with five trials in progress and lots of key milestones to be hit. If the milestones are hit – and Crombie is backing their potential – we should start to see positive movement in the share price. Market cap is only $7.6 million at this stage. Company has around $3 million in cash and is planning a fund raising early next year to fast track drug development. This must be one of the best value biotech investments in Australia. Crombie says his plan would be to partner the assets prior to a phase 3 trial which could happen in the short to medium term. This is when investors could see the real pay-day. Crombie says he knows of no other small cap biotech with this many trials in progress. Click here for further details including a video Dr Rob Crombie discussing the recent AKTivate Therapeutics acquisition.